QuiaPEG Pharmaceuticals Holding AB Asset Resilience Ratio

Latest as of March 2017: 14.02%

QuiaPEG Pharmaceuticals Holding AB asset resilience ratio. QuiaPEG Pharmaceuticals Holding AB (QUIA) has an Asset Resilience Ratio of 14.02% as of March 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See QuiaPEG Pharmaceuticals Holding AB (QUIA) liquidity interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr3.36 Million
≈ $361.83K USD Cash + Short-term Investments

Total Assets

Skr23.99 Million
≈ $2.58 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio of QuiaPEG Pharmaceuticals Holding AB (2010–2010)

Asset resilience ratio of QuiaPEG Pharmaceuticals Holding AB from 2010 to 2010. This chart shows how QuiaPEG Pharmaceuticals Holding AB's Asset Resilience Ratio has changed over time. Read debt load of QuiaPEG Pharmaceuticals Holding AB for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down QuiaPEG Pharmaceuticals Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see QuiaPEG Pharmaceuticals Holding AB asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr0.00 0%
Short-term Investments Skr3.36 Million 14.02%
Total Liquid Assets Skr3.36 Million 14.02%

Asset Resilience Insights

  • Moderate Liquidity: QuiaPEG Pharmaceuticals Holding AB has 14.02% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

QuiaPEG Pharmaceuticals Holding AB Industry Peers by Asset Resilience Ratio

Compare QuiaPEG Pharmaceuticals Holding AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

QuiaPEG Pharmaceuticals Holding AB Asset Resilience Ratio by Year (2010–2010)

QuiaPEG Pharmaceuticals Holding AB asset resilience ratio by year from 2010 to 2010. The table below shows the annual Asset Resilience Ratio data for QuiaPEG Pharmaceuticals Holding AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2010-12-31 24.43% Skr4.86 Million
≈ $522.48K
Skr19.88 Million
≈ $2.14 Million
--
pp = percentage points

About QuiaPEG Pharmaceuticals Holding AB

ST:QUIA Sweden Biotechnology
Market Cap
$141.00K
Skr1.31 Million SEK
Market Cap Rank
#31434 Global
#738 in Sweden
Share Price
Skr0.00
Change (1 day)
-16.67%
52-Week Range
Skr0.00 - Skr0.00
All Time High
Skr464.25
About

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more